Abbott’s MitraClip G4 Receives the US FDA’s Approval for the Treatment of Mitral Regurgitation

 Abbott’s MitraClip G4 Receives the US FDA’s Approval for the Treatment of Mitral Regurgitation

Abbott’s MitraClip G4 Receives the US FDA’s Approval for the Treatment of Mitral Regurgitation

Shots:

  • MitraClip G4 is a fourth-generation MitraClip device offering a new option to physicians for treating leaky mitral valve in the US with an expanded range of clip sizes and leaflet grasping feature
  • MitraClip G4 provides the benefit of an upgraded catheter to allow integrated real-time continuous left atrial pressure monitoring during implant and help physicians to determine the accurate position of MitraClip for optimizing patient outcomes
  • Mitraclip is a device used to prevent backflow of blood and restore the heart’s ability to pump oxygenated blood more efficiently and has received the FDA’s approval for primary and secondary MR in 2013 and 2019 respectively

Click here to read full press release/ article | Ref: Abbott | Image: Pharma Advancement

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post